Market closed

Allogene Therapeutics/$ALLO

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Allogene Therapeutics

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Ticker

$ALLO
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
South San Francisco, United States

Employees

233
Website
www.allogene.com

ALLO Metrics

BasicAdvanced
$409M
-
-$1.54
0.84
-

$409M

0.84

$5.78

$1.78

2.7M

9.346

9.038

18.358

19.951

-2,688.56%

-25.82%

-54.15%

8,369.099

0.88

0.88

-1.649

26.47%

-32.57%

-89.62%

-6.44%

What the Analysts think about ALLO

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Allogene Therapeutics stock.

ALLO Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ALLO Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

ALLO News

AllArticlesVideos
Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewsWire·4 weeks ago
Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman

GlobeNewsWire·1 month ago
Allogene Therapeutics Announces Participation in December Investor Conferences

Allogene Therapeutics Announces Participation in December Investor Conferences

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ALLO

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Allogene Therapeutics stock?

Allogene Therapeutics (ALLO) has a market cap of $409M as of January 15, 2025.

What is the P/E ratio for Allogene Therapeutics stock?

The price to earnings (P/E) ratio for Allogene Therapeutics (ALLO) stock is 0 as of January 15, 2025.

Does Allogene Therapeutics stock pay dividends?

No, Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Allogene Therapeutics dividend payment date?

Allogene Therapeutics (ALLO) stock does not pay dividends to its shareholders.

What is the beta indicator for Allogene Therapeutics?

Allogene Therapeutics (ALLO) has a beta rating of 0.84. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.